Imago Biosciences

Imago BioSciences, Inc. operates as a clinical-stage biopharmaceutical company that develops novel anti-cancer therapeutics. It translates science of genetics and epigenetics enzymes into novel medicines for treating myeloid diseases that pose challenges to patients, families, and physicians. The company also translates insights into transformative therapies that alter the history of disease allowing patients to live longer and disease-free lives. Imago BioSciences was founded by Hugh Young Rienhoff, Jr., Laura G. Eichorn and Jennifer Peppe on March 29, 2012 and is headquartered in Redwood City, CA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck

RAHWAY, N.J. & SOUTH SAN FRANCISCO, Calif.--( BUSINESS WIRE )--Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO) today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Imago for $36.00 per share in cash for an approximate total equity value of $1.35 billion.

Merck to Acquire Imago BioSciences, Inc.

- Data updates for Bomedemstat Phase 2 trials in Essential Thrombocythemia (ET) and Myelofibrosis (MF) to be presented at the American Society of Hematology (ASH) Annual Meeting in December 2022 -

Imago BioSciences Reports Third Quarter 2022 Financial Results and Provides Recent Business Updates

SOUTH SAN FRANCISCO, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering and developing new medicines for the treatment of myeloproliferative neoplasms (MPNs) and other bone marrow diseases, today announced that Hugh Young Rienhoff, Jr., M.D., Imago's Chief Executive Officer, will participate in two upcoming investor conferences.

Imago BioSciences to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering and developing new medicines for the treatment of myeloproliferative neoplasms (MPNs) and other bone marrow diseases, today announced two abstracts have been accepted for oral presentation at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, to be held December 10-13, 2022.

Imago BioSciences Announces Oral Data Presentations at the Upcoming 64th American Society of Hematology Annual Meeting and Exposition

SOUTH SAN FRANCISCO, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical-stage biopharmaceutical company discovering and developing new medicines for the treatment of myeloproliferative neoplasms (MPNs) and other bone marrow diseases, today announced that Hugh Young Rienhoff, Jr., MD, CEO of Imago BioSciences, will participate in the H.C. Wainwright 24th Annual Global Investment Conference taking place September 12 - 14, 2022.

Imago BioSciences to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

The mean of analysts' price targets for Imago BioSciences, Inc. (IMGO) points to an 83.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Think Imago BioSciences, Inc. (IMGO) Could Surge 83%: Read This Before Placing a Bet

- Positive Data from the Ongoing Phase 2 Study of Bomedemstat in Essential Thrombocythemia (ET) Presented at European Hematology Association (EHA) Meeting 2022 -

Imago BioSciences Reports Second Quarter 2022 Financial Results and Provides Recent Business Updates

SOUTH SAN FRANCISCO, Calif., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering and developing new medicines for the treatment of myeloproliferative neoplasms (MPNs) and other bone marrow diseases, today announced that Hugh Young Rienhoff, Jr., MD, CEO of Imago BioSciences, will participate in an analyst led Fireside Chat at the 2022 Wedbush PacGrow Healthcare Conference on August 10, 2022, at 1:10 pm Eastern Time / 10:10 am Pacific Time.

Imago BioSciences to Participate in the 2022 Wedbush PacGrow Healthcare Conference

- As of the data cutoff date of 29 April 2022, in addition to improvements in the standard metrics of spleen volume reduction and symptom scores, long term treatment with bomedemstat showed:

Imago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Advanced Myelofibrosis at EHA 2022

- The study completed enrollment with 73 patients in April 2022 -

Imago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Essential Thrombocythemia at EHA 2022

- Company to host virtual investor event on Saturday, June 11 at 10:30 AM ET following its June 10 th presentation of updated data from Phase 2 studies of bomedemstat for the treatment of Essential Thrombocythemia and Myelofibrosis at the 2022 European Hematology Association (EHA) Congress -

Imago BioSciences to Host Virtual Investor Event

- Completed Type C meeting with FDA to align on study design, study population, control group and primary endpoint for planned Phase 3 essential thrombocythemia (ET) study

Imago BioSciences Reports First Quarter 2022 Financial Results and Provides Recent Business Updates

SOUTH SAN FRANCISCO, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc.  (“Imago”) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering and developing new medicines for the treatment of myeloproliferative neoplasms (MPNs) and other bone marrow diseases, today announced that updated Phase 2 data from its two clinical programs for bomedemstat (IMG-7289) have been accepted for poster presentation at the 27 th Congress of the European Hematology Association for 2022, to be held on June 9-12, 2022 in Vienna, Austria and virtually.

Imago BioSciences Announces Upcoming Presentations on Updated Data from Phase 2 Studies of Bomedemstat for the Treatment of Essential Thrombocythemia and Myelofibrosis at the 27th Congress of the European Hematology Association (EHA) for 2022

SOUTH SAN FRANCISCO, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering and developing new medicines for the treatment of myeloproliferative neoplasms (MPNs) and other bone marrow diseases, today announced that the first participant has been treated in an investigator-sponsored Phase 1/2 study of bomedemstat in combination with atezolizumab (Tencentriq®) during the maintenance phase of treatment in people newly diagnosed with extensive stage small cell lung cancer (ES-SCLC).

Imago BioSciences Announces First Participant Dosed in Investigator-Sponsored Study of Bomedemstat in Combination with Atezolizumab in Small Cell Lung Cancer

Interim Data Update at European Hematology Association (EHA) meeting in June and  Results from Completed Phase 2 Study Expected in Second Half of 2022

Imago BioSciences Announces Completion of Enrollment in Phase 2 Clinical Study of Bomedemstat in Essential Thrombocythemia

SOUTH SAN FRANCISCO, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- ​Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs) and other bone marrow diseases, today reported financial results for the full year ended December 31, 2021.

Imago BioSciences Reports Fourth Quarter and Full Year 2021 Financial Results

Mr. Arenberg brings over 25 years of experience in the biopharmaceutical industry Mr. Arenberg brings over 25 years of experience in the biopharmaceutical industry

Imago BioSciences Appoints Michael Arenberg to Chief Operating and Business Officer

SOUTH SAN FRANCISCO, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- ​Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs), today announced that Hugh Y. Rienhoff, Jr., M.D., Imago's Chief Executive Officer, will participate in the Cowen 42nd Annual Health Care Conference, taking place March 7-9, 2022.

Imago BioSciences to Participate in the Cowen 42nd Annual Health Care Conference

Imago BioSciences (IMGO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Earnings Season Could Be Great for Imago BioSciences (IMGO)

SOUTH SAN FRANCISCO, Calif., Feb. 04, 2022 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs), today announced that Hugh Y. Rienhoff, Jr., M.D., Imago's Chief Executive Officer, will participate in a fireside chat at the Guggenheim Healthcare Talks 2022 Oncology Conference on Thursday, February 10, 2022 at 10:30 a.m. PT / 1:30 p.m. ET.

Imago BioSciences to Participate in Guggenheim Healthcare Talks 2022 Oncology Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $IMGO #ASH21--Imago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Essential Thrombocythemia at ASH 2021

Imago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Essential Thrombocythemia at ASH 2021

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $IMGO #ASH21--Imago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Advanced Myelofibrosis at ASH 2021

Imago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Advanced Myelofibrosis at ASH 2021

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Imago BioSciences, Inc. (Imago) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs), today announced the appointment of Laurie Keating to its Board of Directors on November 17, 2021. Keating is a seasoned executive, with nearly two decades of her 40-year career in diverse roles within the biopharmaceutical industry. “I am pleased to welcome to Laurie to Imago's

Imago BioSciences Appoints Laurie Keating to Board of Directors

SOUTH SAN FRANCISCO, Calif., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs), today announced that Hugh Y. Rienhoff, Jr., M.D., Imago's Chief Executive Officer, will present at the Stifel 2021 Virtual Healthcare Conference on Tuesday, November 16, 2021, at 10:40 a.m. ET.

Imago BioSciences to Present at Stifel 2021 Virtual Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical-stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs), today reported financial results for the third quarter ended September 30, 2021 and highlighted recent corporate updates.

News for Imago Biosciences Stock (IMGO)